BioMarin Pharmaceutical traded at $82.87 this Thursday June 30th, decreasing $1.05 or 1.25 percent since the previous trading session. Looking back, over the last four weeks, BioMarin Pharmaceutical lost 10.30 percent. Over the last 12 months, its price fell by 1.24 percent. Looking ahead, we forecast BioMarin Pharmaceutical to be priced at 84.51 by the end of this quarter and at 77.88 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Acadia Pharmaceuticals 14.09 -0.13 -0.91% -43.12%
Acorda Therapeutics 0.47 0.02 4.25% -89.92%
Agios Pharmaceuticals 22.17 -0.21 -0.94% -60.71%
Alnylam Pharmaceuticals 145.85 0.42 0.29% -14.08%
Amgen 242.26 -1.04 -0.43% -1.88%
Bayer 56.90 0.18 0.32% 10.55%
Biogen 204.68 0.74 0.36% -41.34%
Bluebird Bio 4.14 -0.44 -9.61% -87.23%
BioMarin Pharmaceutical 82.87 -1.05 -1.25% -1.24%
Gilead Sciences 61.39 -0.42 -0.68% -11.20%
Intercept Pharmaceuticals 13.97 0.16 1.16% -31.75%
Incyte Corp 76.38 0.41 0.54% -9.09%
Insmed 19.88 0.16 0.81% -32.54%
Ionis Pharmaceuticals 37.67 0.65 1.76% -5.94%
Moderna Inc 147.76 4.91 3.44% -37.15%
Neurocrine Biosciences 98.41 0.93 0.95% 0.97%
Puma Biotechnology 2.89 0.04 1.40% -69.22%
PTC Therapeutics 41.30 1.24 3.10% -4.15%
Ultragenyx Pharmaceutical 61.56 1.90 3.18% -34.66%
Regeneron Pharmaceuticals 586.64 -4.49 -0.76% 0.51%
Roche Holding 320.60 2.05 0.64% -8.28%
Seattle Genetics 177.05 0.11 0.06% 12.58%
Sangamo BioSciences 4.26 0.12 2.78% -63.66%
Sanofi 50.21 0.18 0.35% -4.48%
Sarepta Therapeutics 76.00 1.04 1.39% 1.01%
United Therapeutics 234.93 -0.71 -0.30% 27.45%
Vertex Pharmaceuticals 282.68 0.89 0.32% 40.96%

Indexes Price Day Year
USND 10932 -97.00 -0.88% -25.33%

BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.